[ad_1] Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. …
Tag: Biogen Inc
More convenient form of breakthrough Alzheimer’s drug Leqembi shows promising results in study
[ad_1] Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more…
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drug
[ad_1] In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket |…
Bipartisan attorneys general call on Medicare to cover Alzheimer’s treatments
[ad_1] Democratic and Republican attorneys general in nearly half of U.S. states are calling on Medicare to provide unrestricted coverage of antibody treatments for Alzheimer’s disease, according to a letter…
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
[ad_1] Juanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more broadly in the…
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
[ad_1] A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration on Tuesday…
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
[ad_1] A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli…
Here’s where to look for the next developments in the fight against Alzheimer’s disease
[ad_1] Biogen and its partner, Japanese drugmaker Eisai , earlier this month received accelerated approval from the Food and Drug Administration for Leqembi, a monoclonal antibody to treat Alzheimer’s disease.…
FDA approves Alzheimer’s drug that slowed cognitive decline in clinical trial
[ad_1] MRI image of brain showing area of Alzheimer patient. Getty Images The Food and Drug Administration on Friday granted accelerated approval for the Alzheimer’s drug lecanemab, developed by Biogen…